Tirzepatide ("Mounjaro") first developed by organization Eli Lilly, is the first dual GIP/GLP1 receptor agonist approved by the "FDA" in May 2022 to treat Type 2 Diabetes (T2D). Works by targeting two metabolic pathways, resulting in effective blood sugar regulation and substantial weight reduction. Clinical trials showed better HbA1c and weight outcomes compared to GLP-1 therapies while maintaining a similar safety profile, positioning it as a significant advancement for T2D treatment.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Tirzepatide by Dragon Pharma, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
